Loading patent…
AssigneeCold Spring Harbor Laboratory
InventorsDavid H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
Estimating the term…
The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
A method for inhibiting uncontrolled proliferation of a cell, comprising contacting a cell deficient in wild-type p16 in vitro with a gene delivery composition for delivering a nucleic acid construct comprising a nucleic acid sequence which hybridizes at conditions of 2×SSC at 50° C. or higher stringency to a nucleic acid sequence of SEQ ID No:
A method for inhibiting restenosis in an individual, comprising administering at or adjacent to the site of said restenosis a gene delivery composition for delivering a nucleic acid construct comprising a nucleic acid sequence which hybridizes at conditions of 2×SSC at 50° C. or higher stringency to a nucleic acid sequence of SEQ ID No:
A method for inhibiting uncontrolled proliferation of a cell deficient in wild-type p16, comprising contacting the cell in vitro with a gene delivery composition for delivering a nucleic acid construct comprising a nucleic acid sequence which encodes a p16 polypeptide sequence including ankyrin repeats, wherein said p16 polypeptide sequence is at least 90% identical to an amino acid sequence of SEQ ID No:
A method for inhibiting restenosis in an individual, comprising administering at or adjacent to the site of said restenosis a gene delivery composition for delivering a nucleic acid construct comprising a nucleic acid sequence which encodes a p16 polypeptide sequence including ankyrin repeats, wherein said p16 polypeptide is at least 90% identical to an amino acid sequence of SEQ ID No:
Dependencies are inferred from the claim text.